The study, published in the Journal of Neuro-Oncology, tackles a problem that has grown more pressing as whole-brain radiation therapy has fallen out of favor. Brain metastases, the spread of cancer to the brain from tumors elsewhere in the body, are estimated to occur in a substantial fraction of patients with advanced cancer, and as systemic therapies extend survival, more patients live long enough to face complications in the brain itself. Modern guidelines from ASTRO, ASCO, and the Society for Neuro-Oncology favor stereotactic radiosurgery, which concentrates high radiation doses on individual tumors while sparing healthy tissue. But large lesions, defined in this study as those with a volume of at least 4 cubic centimeters, pose a special challenge. A single massive dose of radiation risks injuring surrounding brain tissue, so clinicians must choose between single-session treatment, splitting the dose into staged sessions weeks apart, or delivering it in a handful of larger-than-conventional fractions known as hypofractionation. Which strategy works best, and at what dose, has remained genuinely uncertain.

The research team, led by Yuta Koketsu and corresponding author Toshinori Hasegawa, took advantage of a decade of experience at a single Gamma Knife center. Between 2016 and 2024, they treated patients with large brain metastases using all three approaches, individualizing both the treatment schedule and the radiation dose to each patient’s anatomy and clinical situation. For the analysis, they focused on one dominant lesion per patient and tracked it with serial imaging. Radiographic progression was defined conservatively as an increase of at least 20 percent in the longest tumor diameter from its smallest recorded size, the nadir. But the investigators went a crucial step further than most radiographic studies. They distinguished true progression, meaning enlargement that persisted or forced the team to intervene with additional treatment, from pseudoprogression, in which a lesion that initially appeared to grow later stabilized or shrank on its own without any salvage therapy. This distinction matters enormously, because treating pseudoprogression with more radiation or surgery exposes patients to harm for a problem that would have resolved by itself.

The headline result concerns dose. Using the concept of biologically effective dose, a radiobiological formula that converts different dose-and-fractionation schedules into a single number reflecting the expected biological effect on tumor cells, the team found a clear threshold. Lesions that received a BED10 of at least 57.6 Gy had a significantly lower risk of true progression, with a subdistribution hazard ratio of 0.46, meaning the hazard was cut by more than half, and the difference was statistically significant at p equals 0.02. In practical terms, the BED10 framework rewards clinicians for thinking beyond the raw dose number on a treatment plan. A modest dose delivered in a single session and a larger total dose spread over several sessions can be biologically equivalent to tumor cells, and the 57.6 Gy threshold gives clinicians a common currency for comparing schedules. Notably, the analysis found that true progression rates did not differ significantly by treatment modality, whether single-session, staged, or hypofractionated, or by tumor volume, suggesting that what matters is the total biological punch delivered rather than the specific way it is packaged.

The cumulative incidence figures tell the story of what patients face over time. At six months after Gamma Knife surgery, 17.4 percent of lesions had undergone true progression. By twelve months, that figure had climbed to 31.5 percent, and by twenty-four months it had essentially plateaued at 33.1 percent. That plateau is clinically meaningful: it suggests that if a large treated metastasis is going to truly regrow, it almost always does so within the first year, and a patient who reaches the two-year mark with local control is unlikely to lose it. The median overall survival of the entire cohort was 15.3 months, which means that for a large share of these patients, the question of local tumor control is not academic; it unfolds within their actual lifespan and directly affects their quality of life and neurological function.

Of the 143 lesions followed, 47 eventually showed radiographic progression, but the breakdown reveals how treacherous imaging interpretation can be. Forty-two turned out to be true progression, four were pseudoprogression, and one was attributed to intratumoral hemorrhage. In other words, roughly one in ten radiographic failures was not a failure at all. The pseudoprogression phenomenon reflects radiation necrosis, a delayed injury to brain tissue in and around the treated lesion that can cause the enhancing area on MRI to enlarge, mimic tumor growth, produce mass effect and edema, and even bring back a patient’s original neurological symptoms. Biopsy series from other centers have repeatedly shown that enlarging lesions after radiosurgery frequently contain necrosis rather than viable tumor. The Komaki team illustrated the point vividly in a supplementary case: a man in his seventies with a 66 cubic centimeter occipital metastasis causing hemianopsia and Gerstmann syndrome received two-stage Gamma Knife treatment with 12 Gy per stage. His symptoms resolved and the tumor shrank dramatically, but a year later the lesion enlarged again with worsening edema and recurrent vision loss, apparently demanding salvage therapy. Instead, it stabilized on its own at eighteen months and the edema improved by twenty-two months, consistent with radiation necrosis running its natural course.

How, then, can clinicians tell the impostor from the real thing? The study’s most actionable finding is a timing signature. Recurrent peritumoral edema, the reappearance or worsening of fluid accumulation in brain tissue around the lesion, developed far earlier in true progression than in pseudoprogression, with a median of 173.5 days versus 564 days, a difference that was highly significant at p equals 0.001. When tumor enlargement and renewed edema arrive together within roughly the first year after treatment, the pattern strongly indicates genuine tumor regrowth, and the authors conclude that such a finding should prompt consideration of early salvage intervention rather than a prolonged wait-and-see approach. Conversely, enlargement with edema emerging well beyond the one-year mark is more consistent with late radiation necrosis, where observation may spare the patient unnecessary surgery or reirradiation. This simple temporal rule requires no advanced imaging, no perfusion sequences, no spectroscopy, and no biopsy, only careful attention to the calendar alongside the MRI.

The study also speaks to what happens when a lesion does fail and clinicians reach for a second round of Gamma Knife treatment. Among patients who underwent repeat radiosurgery, a lower marginal dose at the second session was associated with subsequent true progression, with a hazard ratio of 0.82 per dose increment, significant at p equals 0.02. The interpretation is sobering: underdosing at salvage treatment appears to invite another failure, yet pushing the dose higher raises the specter of radiation necrosis, particularly since the surrounding tissue has already been irradiated. Repeat stereotactic radiosurgery for recurrent brain metastases is well established in the literature, with systematic reviews and meta-analyses documenting both its efficacy and its necrosis risk, and the new data add a quantitative argument for dosing salvage sessions deliberately rather than timidly. The team notes that their institution has also explored combined approaches, including reirradiation followed by resection, for select recurrent lesions.

Why does dose matter so much biologically? The answer lies in classic radiation biology. Tumor cells vary in their oxygenation, and cells at intermediate oxygen levels can substantially influence the response of a tumor to fractionated radiotherapy, a relationship explored in foundational work by Wouters and Brown. Hypoxic cells require more radiation to kill, and fractionation schedules that allow tumor reoxygenation between sessions can partially compensate, which is precisely why the BED10 framework, which encodes the effect of fractionation, is a better predictor of control than the physical dose alone. Large metastases are also more likely than small ones to contain poorly oxygenated cores and to press against eloquent brain structures that force dose reductions, creating a tension between tumor control and toxicity that the 57.6 Gy threshold helps clinicians navigate quantitatively.

The study’s limitations are those inherent to its design: it was retrospective, conducted at a single institution, and treatment decisions were individualized rather than randomized, so selection biases cannot be fully excluded. Datasets are available from the corresponding author on reasonable request, and the work received no specific external funding. Still, the practical takeaways are hard to ignore. For patients with large brain metastases, the total biologically effective dose delivered to the tumor edge should be planned to reach at least 57.6 Gy BED10, using whatever fractionation scheme best protects the surrounding brain. And in follow-up, the pairing of tumor enlargement with recurrent peritumoral edema within a year of Gamma Knife surgery should be read not as an ambiguous radiological curiosity but as a call to act, because in this disease, waiting for certainty can cost patients the window in which salvage treatment works best.

Subject of Research: Dose selection and progression assessment after Gamma Knife radiosurgery for large brain metastases

Article Title: Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression

Article References: Koketsu, Y., Hasegawa, T., Kato, T., Naito, T., Mizuno, A., Ando, Y., Kosaka, N., & Saito, R. (2026). Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression. Journal of Neuro-Oncology, 180(1), Article 3. https://doi.org/10.1007/s11060-026-05792-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05792-0

Keywords: Gamma Knife surgery, stereotactic radiosurgery, brain metastases, biologically effective dose, pseudoprogression, radiation necrosis, peritumoral edema, salvage therapy, hypofractionation, tumor progression, radiation oncology, neuro-oncology

The work, led by Jheremy S. Reyes, Constantinos G. Hadjipanayis, L. Dade Lunsford, and Ajay Niranjan at the University of Pittsburgh Medical Center’s Center for Image-Guided Neurosurgery, addresses a population that has long been underserved by predictive modeling. Brain metastases from gastrointestinal primaries, including colorectal, pancreatic, gastric, and biliary cancers, are biologically heterogeneous and historically associated with poorer local control than metastases from lung or breast cancers. Because these tumors are relatively less common in the radiosurgery literature, dose selection for them has been extrapolated from broader metastasis cohorts rather than tailored to their specific behavior. The Pittsburgh team set out to build a model trained specifically on this patient group.

At the heart of the framework is a machine learning architecture known as a mixture of experts, a concept that dates back to foundational work by Jacobs, Jordan, Nowlan, and Hinton in 1991 and was later formalized hierarchically by Jordan and Jacobs. Rather than forcing a single neural network to learn every pattern in the data, a mixture-of-experts model divides the problem among several specialized subnetworks, each of which becomes adept at a particular region of the clinical feature space. A gating network then learns which expert to trust for a given patient, weighting their contributions accordingly. In THINKERS-GI, three such experts operate in parallel, allowing the model to capture distinct subpopulations among GI brain metastasis patients whose tumors and outcomes behave in fundamentally different ways.

The technical machinery beneath the experts is equally deliberate. The framework employs discrete-time competing-risk survival modeling, a statistical approach that estimates the probability of an event, such as local tumor failure, over successive time intervals while explicitly accounting for competing events that can preclude that failure, most notably death from systemic disease. This matters enormously in brain metastases, where many patients have limited life expectancies driven by their systemic cancer, and a model that ignores competing risks will systematically overestimate the benefit of aggressive local therapy. By modeling both local failure and adverse radiation effects in this competing-risk framework, THINKERS-GI can express its outputs as time-dependent probabilities rather than crude binary classifications.

One of the most clinically significant design choices is that the margin dose, the radiation dose prescribed at the edge of the tumor, was built into the model as a queryable input. This transforms the network from a passive outcome predictor into an active decision-support tool. A clinician can ask the model a counterfactual question: what would the predicted probability of local control and of adverse radiation effects be if this lesion received 18 Gy instead of 16 Gy? By sweeping across a range of candidate doses, the framework generates a dose-response profile unique to each lesion, effectively allowing the care team to explore the trade-off between tumor control and toxicity before the first beam is ever delivered.

The study drew on a retrospective single-center cohort of 300 patients treated with Gamma Knife radiosurgery, encompassing 1,233 individual GI brain metastases. Pretreatment clinical and lesion-level variables were used to train the network, and the authors took validation seriously, employing grouped five-fold cross-validation alongside a closed, grouped holdout set. Grouping is a crucial methodological safeguard in this setting: because a single patient can contribute many lesions, randomly splitting lesions across training and test sets would leak patient-specific information and inflate performance estimates. By keeping all lesions from one patient together, the researchers ensured that their reported metrics reflect genuine generalization to unseen patients.

The results were strong by the standards of clinical prediction modeling. In grouped cross-validation, the time-dependent area under the curve ranged from 0.808 to 0.894, with a concordance index of 0.889 plus or minus 0.034, indicating good discrimination between patients who experienced local failure and those who did not. The calibrated twelve-month Brier score, which penalizes both poor discrimination and poor calibration, was a remarkably low 0.019 plus or minus 0.013, and the mean absolute error for predicting the time to local failure was just 1.8 plus or minus 0.7 months. On the more demanding grouped holdout set, performance remained respectable, with a twelve-month AUC of 0.806, a C-index of 0.781, a calibrated Brier score of 0.101, and a mean absolute error for time-to-failure of 1.27 months.

The dose-sweeping experiments offer a glimpse of what routine clinical use might look like. When the framework evaluated candidate doses across the cohort, it selected a dose within two Gy of the dose actually delivered by physicians in 91.8 percent of lesions, a striking signal that the model’s reasoning converges with expert clinical judgment in the vast majority of routine cases. More intriguingly, in the cases where the model suggested deviations, the simulated optimization increased the predicted twelve-month local control rate from 82.3 percent to 84.4 percent while simultaneously reducing the predicted risk of adverse radiation effects from 7.9 percent to 7.6 percent. Improving both endpoints at once is the holy grail of radiation dose optimization, since these outcomes typically pull in opposite directions.

The THINKERS-GI study is not an isolated effort but part of a rapidly expanding research program from the Pittsburgh group, which has applied the same hybrid intelligence philosophy to meningiomas, glioblastomas, vestibular schwannomas, lung cancer brain metastases, melanoma brain metastases, pituitary adenomas, craniopharyngiomas, and post-resection cavities. This disease-specific strategy reflects a growing recognition in oncology AI that a single general-purpose model often performs worse than a family of specialized ones, particularly for rare tumor types with distinctive biology. Related work elsewhere, such as the MoE-Surv framework for rare cancers, has reached similar conclusions, suggesting that mixture-of-experts architectures may become a standard tool for survival prediction in oncology.

Important caveats remain before such tools reach the treatment planning console. The study was retrospective and single-center, and the authors describe their work as internally validated, meaning the model has not yet been tested on patients from other institutions with different treatment protocols and patient populations. External validation, and eventually prospective evaluation, will be essential to establish that the framework’s dose recommendations translate into genuinely better outcomes rather than merely better predictions. The authors also note that no external datasets were generated or analyzed in the current study, underscoring that this is a foundation rather than a finished clinical product. Still, the combination of rigorous competing-risk survival modeling, patient-grouped validation, and queryable dose inputs marks a meaningful step toward a future in which every radiosurgery prescription is informed by an individualized estimate of what the treatment is likely to achieve, and what it is likely to cost the surrounding brain.

Subject of Research: A mixture-of-experts AI framework for predicting outcomes and optimizing radiation doses in gastrointestinal brain metastases treated with Gamma Knife radiosurgery

Article Title: Therapeutic hybrid intelligence with neural and knowledge-based expert reasoning for SRS (THINKERS): a mixture-of-experts framework for gastrointestinal brain metastases

Article References: Reyes, J. S., Hadjipanayis, C. G., Lunsford, L. D., & Niranjan, A. (2026). Therapeutic hybrid intelligence with neural and knowledge-based expert reasoning for SRS (THINKERS): a mixture-of-experts framework for gastrointestinal brain metastases. Journal of Neuro-Oncology, 179(2), Article 68. https://doi.org/10.1007/s11060-026-05781-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05781-3

Keywords: brain metastases, gastrointestinal cancer, Gamma Knife radiosurgery, artificial intelligence, mixture of experts, dose optimization, survival modeling, local control, radiation toxicity, predictive modeling, neuro-oncology, competing risks

The fundamental concept behind Gamma Knife technology is to deliver a precisely focused dose of high-dose radiation to targeted brain tumors while minimizing exposure to surrounding healthy tissues. The pivotal distinction in this study centers around the dose rate—a variable that can substantially affect tumor control and patient safety. Researchers conducted a detailed analysis revealing how different dose rates could lead to varied outcomes in terms of tumor response and side effects, bringing to light essential considerations for clinical decision-making.

Clinicians have long noted the complexities associated with treating brain metastases. The involvement of multiple tumor-specific factors complicates treatment protocols. Erdoğan and his team categorized various tumor types ranging from lung cancers to breast cancers, observing how the biological makeup of these malignancies can dictate the tumor’s response to GKS. Their study highlights the importance of personalizing treatment plans based on tumor-specific characteristics—a paradigm shift that paves the way for tailored oncology and improved patient outcomes.

One of the critical findings from the cohort study shows a direct correlation between the dose rate of radiation and the long-term control of brain metastases. Higher dose rates were associated with improved local tumor control, suggesting that optimizing the GKS can enhance its effectiveness in managing advanced disease stages. This discovery urges radiologists and oncologists to rethink current treatment protocols to embrace higher dose rates, which may lead to better patient prognoses.

Additionally, patient selection is paramount in the context of brain metastases. Erdoğan et al. identified specific patient characteristics that influence outcomes, including age, overall health status, and previous treatment histories. For instance, younger patients with fewer comorbidities tended to exhibit better responses to GKS when compared to older patients with multiple health issues. This aspect underscores the necessity for an interdisciplinary approach in oncology, where specialists can collaboratively assess a patient’s comprehensive health background alongside tumor specifics.

The study also delves into the potential side effects associated with different dose rates. While higher dose rates promise better tumor control, they are not without risks. The team emphasized the need for vigilance in monitoring patients for side effects such as radiation necrosis, which can impede quality of life. By addressing these concerns, the research advocates for a balanced approach in prescribing gamma knife treatments, whereby the benefits are carefully weighed against potential adverse effects.

Another noteworthy observation was the role of tumor morphology in treatment outcomes. Certain tumor types demonstrated a marked resistance to radiation despite higher dose rates. For instance, melanoma brain metastases were found to have a significantly different radiation response compared to adenocarcinoma. Erdogan and colleagues elucidated how understanding these nuances could help refine treatment strategies, potentially leading to the integration of adjuvant therapies alongside GKS to improve overall efficacy.

Moreover, the treatment outcomes were also influenced by tumor location within the brain. Tumors located in eloquent areas, such as those close to critical functional regions, posed significant challenges in achieving optimal control without compromising neurological function. The study highlights how innovative imaging techniques can assist in better targeting during GKS, thereby potentially improving the therapeutic index and mitigating the risks associated with radiation.

Patient-reported outcomes play a crucial role in assessing the effectiveness of gamma knife surgery, and this research takes that into consideration. Erdoğan et al. collected patient feedback regarding their experiences during treatment and the subsequent changes in their quality of life. The integration of these subjective measures into clinical studies emphasizes the importance of holistic patient care and can guide providers in tailoring post-treatment interventions.

As the field of oncology continues to evolve, the integration of artificial intelligence and machine learning presents exciting opportunities for enhancing gamma knife surgery’s effectiveness. The study hints at the potential of predictive analytics to develop models that could forecast treatment responses based on pre-treatment parameters. Such innovations could lead to more precise dosing strategies and contribute to the overall personalization of cancer care.

In conclusion, the insights forwarded by Erdoğan et al. present a compelling narrative on the multifactorial influences affecting gamma knife treatment outcomes in brain metastases. This cohort study elucidates the critical interplay between dose rates and tumor-specific characteristics, advocating for personalized treatment protocols. As the treatment landscape for brain metastases becomes increasingly sophisticated, these findings underscore the importance of continued research and dialogue within the medical community, ensuring that patients receive the most effective therapies tailored to their unique circumstances.

As we look to the future, ongoing investigations into optimizing gamma knife techniques and exploring patient-specific factors are essential in advancing our understanding of brain metastases treatment. This study represents a significant contribution to the growing body of research aiming to enhance individual patient care and improve long-term survival rates in those battling this challenging condition.

The concluding remarks center on the urgent need to implement the findings of this research into clinical practice. The call for standardized treatment protocols that incorporate the established dose rates and tumor-specific strategies suggests a promising shift in how we approach the management of brain metastases. The implications of this study echo through the halls of oncology departments worldwide, emphasizing the need for collaborative, evidence-based practices that could redefine patient care in this challenging area of medicine.

In light of such transformative findings, the scientific community stands poised to embrace the next generation of treatment paradigms for brain metastases, fostering a collaborative approach towards eradicating cancer.

Subject of Research: The effect of gamma knife dose rate and tumor-specific factors on treatment outcomes in brain metastases

Article Title: Effect of gamma knife dose rate and tumor-specific factors on treatment outcomes in brain metastases: insights from a cohort study

Article References:

Erdoğan, O., Fidan, A., Sakar, M. et al. Effect of gamma knife dose rate and tumor-specific factors on treatment outcomes in brain metastases: insights from a cohort study.
J Cancer Res Clin Oncol 151, 266 (2025). https://doi.org/10.1007/s00432-025-06322-7

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06322-7

Keywords: gamma knife, radiosurgery, brain metastases, treatment outcomes, dose rate, tumor-specific factors, patient care, oncology.